<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818740</url>
  </required_header>
  <id_info>
    <org_study_id>3098003</org_study_id>
    <nct_id>NCT00818740</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of ORM-12741 in Healthy Volunteers</brief_title>
  <official_title>Pharmacokinetics of ORM-12741 After Intravenous and Oral Administration and Effects of Food on ORM-12741 Pharmacokinetics; An Open, Randomised, Single Dose, Single Centre, Crossover Study in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine pharmacokinetic parameters of ORM-12741 in healthy&#xD;
      volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic variables including: Peak concentration in plasma (Cmax), Time to peak concentration in plasma (tmax), Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>96 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety variables including blood pressure (BP), heart rate (HR), electrocardiograms (ECGs), physical examination, laboratory safety variables (haematology, chemistry, serology and urinalysis) and adverse events (AEs).</measure>
    <time_frame>throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ORM-12741 i.v.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ORM-12741 oral solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ORM-12741 oral capsule with food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ORM-12741 oral capsule without food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORM-12741</intervention_name>
    <description>i.v., oral solution and oral capsule forms. Oral capsule given with and without food.</description>
    <arm_group_label>ORM-12741 i.v.</arm_group_label>
    <arm_group_label>ORM-12741 oral capsule with food</arm_group_label>
    <arm_group_label>ORM-12741 oral capsule without food</arm_group_label>
    <arm_group_label>ORM-12741 oral solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Written informed consent (IC) obtained.&#xD;
&#xD;
          -  Good general health ascertained by detailed medical history and physical examinations.&#xD;
&#xD;
          -  Finnish speaking males between 18 and 45 years of age (inclusive).&#xD;
&#xD;
          -  Body Mass Index (BMI) between 18-30 kg/m2 (inclusive, BMI = weight/height2).&#xD;
&#xD;
          -  Weight of 55-100 kg (inclusive).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  A predictable poor compliance or inability to communicate well with the investigator.&#xD;
&#xD;
          -  Veins unsuitable for repeated venipuncture.&#xD;
&#xD;
          -  Evidence of clinically significant cardiovascular, renal, hepatic, haematological,&#xD;
             gastrointestinal, pulmonary, metabolic-endocrine, neurological, urogenital or&#xD;
             psychiatric disease as judged by the investigator.&#xD;
&#xD;
          -  Any condition requiring regular concomitant medication including herbal products or&#xD;
             likely to need any concomitant treatment during the study.&#xD;
&#xD;
          -  Susceptibility to severe allergic reactions.&#xD;
&#xD;
          -  Intake of any medication that could affect the outcome of the study, within 2 weeks&#xD;
             prior to the first study treatment administration or less than 5 times a half-live of&#xD;
             the medication. Possible enzyme inducing drugs will be discussed case-by-case with the&#xD;
             sponsor.&#xD;
&#xD;
          -  Regular consumption of more than 21 units of alcohol per week (1 unit = 4 cl spirits,&#xD;
             about 13 g of alcohol).&#xD;
&#xD;
          -  Current use of nicotine-containing products more than 5 cigarettes or equivalent/day.&#xD;
&#xD;
          -  Inability to refrain from using nicotine-containing products during the stay at the&#xD;
             study centre.&#xD;
&#xD;
          -  Inability to refrain from consuming caffeine-containing beverages during the stay at&#xD;
             the study centre e.g. propensity in getting headache when refraining from&#xD;
             caffeine-containing beverages.&#xD;
&#xD;
          -  Blood donation or loss of significant amount of blood within 2 months prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Abnormal 12-lead ECG finding of clinical relevance after 10-minute rest in supine&#xD;
             position at the screening visit, for example:&#xD;
&#xD;
          -  QTc (calculated through the Bazett's formula) &gt; 450msec,&#xD;
&#xD;
          -  PR &lt; 120 msec or &gt; 210 msec,&#xD;
&#xD;
          -  QRS &lt; 70 msec or &gt; 120 msec.&#xD;
&#xD;
          -  HR &lt; 45 beats/minute or &gt; 100 beats/minute after 10-minute rest in supine position at&#xD;
             the screening visit.&#xD;
&#xD;
          -  At the screening visit systolic blood pressure (BP) &lt; 90 mmHg or &gt; 140 mmHg after 10&#xD;
             minutes in supine position, diastolic BP &lt; 50 mmHg or &gt; 90 mmHg after 10 minutes in&#xD;
             supine position.&#xD;
&#xD;
          -  Any abnormal value of laboratory, vital signs, physical examination, which may in the&#xD;
             opinion of the investigator interfere with the interpretation of the test results or&#xD;
             cause a health risk for the subject if he takes part into the study.&#xD;
&#xD;
          -  History of drug abuse or positive result in drug abuse test.&#xD;
&#xD;
          -  Positive serology to human immunodeficiency virus antibodies (HIVAgAb), hepatitis C&#xD;
             virus antibodies (HCVAb) or hepatitis B surface antigen (HBsAg).&#xD;
&#xD;
          -  Any other condition that in the opinion of the investigator would interfere with the&#xD;
             evaluation of the results or constitute a health risk for the study subject.&#xD;
&#xD;
          -  Participation in a clinical drug study within 3 months prior to the first study&#xD;
             treatment administration of this study or earlier participation in a clinical study&#xD;
             with ORM-12741.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juha Peltonen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRST</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Virpi Mononen</last_name>
    <role>Study Director</role>
    <affiliation>Orion Corporation, Orion Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRST</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>December 22, 2008</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <last_update_submitted>October 7, 2009</last_update_submitted>
  <last_update_submitted_qc>October 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mononen/Clinical Study Manager</name_title>
    <organization>R&amp;D</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

